Alfred Slanetz, PhD, ME, Founder and CEO
Dr. Slanetz is the founder of the Company and has been President, Chief Executive Officer and a director of the Company full time since its inception. Prior to co-founding the Company, he served as Chief Executive Officer and President of Genetix Pharmaceuticals, Inc. Dr. Slanetz served as Vice President, Business Development of TRANSGENE in May 1996. From 1994 to 1996, he served as Manager, New Product Planning and Development at Genentech Inc. Prior to that, Dr. Slanetz was a Management Consultant for Arthur D. Little. He received his Ph.D. in Molecular and Immunobiology from Yale University.
Sanjay Srinivasan, Ph.D., MBA, Chief Business Officer
Dr. Srinivasan has over 25 years of work experience in life science start-ups, specialty chemicals, manufacturing, and in management consulting. He has a track record of commercializing specialty chemical products and polymers, increasing revenues and profits, growing market share as well as in operations, and raising capital. He has worked with early stage life science/healthcare companies in therapeutics, medical devices, and diagnostics in business development and capital raise. He worked at IBM as a management consultant delivering management consulting solutions to Fortune 1000 clients in the areas of strategy implementation, supply chain optimization, business transformation, change management, and in business development. At Ethyl Corporation and Afton Chemical, a Fortune 1000 specialty chemical company, he worked as a scientist and technology group leader. As a team member he developed novel specialty chemical formulations and polymers for multinational companies that contributed to generation of over $1B in revenue, over $250M in operating profits, and an increase in market share of specialty chemical products. At Afton Chemical is he was responsible for a $150M P&L for specialty polymers segment where he turned around the business, managed R&D projects, commercialized and marketed new products, initiated process improvements, and led supply chain management, manufacturing, and sales and marketing activities. As a founder of Accent Advisors, a life sciences/healthcare management consulting company, he provides integrated business, technology innovation, operations, and commercialization solutions to companies in life sciences, pharma, medical devices, and diagnostics in the areas of business development, capital raise, innovation management, and operations. He has 15 US and European patents and has published papers in scientific peer reviewed journals.
Renier Brentjens, MD, Scientific and Clinical Advisor
Co-Founder JUNO Therapeutics. Director, Cell Therapy Memorial Sloan-Kettering (MSK). As a medical oncology fellow at MSK Cancer Center, Dr. Brentjens began the first studies that demonstrated the potential clinical application of autologous T cells genetically modified to target the CD19 antigen through the retroviral gene transfer of artificial T cell receptors (CARs). Work in his lab expanded this technology to target additional tumor antigens.
Marc Better, PhD, Scientific, Manufacturing and Regulatory Advisor
A biotechnology professional with more than 25 years’ experience in cell therapy and biologics CMC. Dr. Better led process and analytical development, process characterization and process validation efforts resulting in the successful U.S. licensure of Yescarta, a first in class anti-CD19 CAR T cell therapy. SVP Product Sciences (process development & manufacturing) at Kite Pharma, Inc. Executive Director, Process Science at Boehringer Ingelheim. Executive Director, Process Development at Amgen.
Kuldip Sra, Vice President Technical Operations and Quality
A biopharma professional with more than 30 years’ experience in Vaccines, Cell therapy, Crispr
Gene Editing and Vectors. Dr. Sra has worked on commercialization of 5 drug products’ and
worked on submissions of over 15 INDs. Dr. Sra led Late-Stage Development at Crispr
Therapeutics. At Kite/Gilead, Dr. Sra was head of QC Clinicals where he led assays development,
validation and tech transfer of lot release analytical assays and BLA submission which helped in
the successful U.S. licensure of Yescarta®, a first in class anti-CD19 CAR T cell therapy and
subsequently also worked on Kite Pharma second licensed product Tecartus® for Mantle Cell
Lymphoma. Dr. Sra worked over 15 years at MedImmune/Astra Zeneca in different capacities
where he was involved in commercialization of three vaccine products.
Paul Abrams, MD, JD, Executive Director
Paul’s major motivation for his entire career has been to improve outcomes for patients, especially those with cancer. He is a board-certified oncologist who was trained at the National Cancer Institute, where he later became their Cancer Expert. He has over 25 years’ experience as President & Chief Executive Officer, Board Member and Adviser of publicly-traded and private companies in biotechnology with a scientific and medical background in tumor immunology, translational medicine and clinical oncology. Paul was Medical Director and later CEO and Director of NeoRx Corporation, a publicly-traded monoclonal antibody-focused oncology company, and President, CEO and Director of CEPTYR, Inc., a privately-held diabetes company. He also served as transitional CEO for Nexgen, a medical device company. He was Board Chair of Aptein, Inc., sold to Cambridge Antibody Technologies, then sold to Astra-Zeneca. He was elected to the Executive Committee of the Biotechnology Industry Association, and the Board of the E. Donnall Thomas Award Committee. He is inventor on 12 US Patents and editor of “The Biology of Lung Cancer” and “Radioimmunotherapy”. He received his M.D. and J.D. from Yale University, graduated summa cum laude from Yale College, where he was a member of Phi Beta Kappa and earned a Varsity Letter in Swimming (butterfly).
12 Michigan Drive
Natick, MA 01760
Ph: (781) 856-7589